Neurocrine Biosciences' (NBIX) exposure to Food and Drug Administration or tariff-related concerns is relatively less compared with its peers, RBC Capital Markets analyst team said Monday in a research note.
Amid weakness in the broader sector and the analysts' expectations for the company's Ingrezza commercial franchise to remain "relatively solid and durable" in the longer term, the firm notes that the company's stock is trading "well below fundamental fair value" and offers a "buying opportunity."
The team upgraded the stock to outperform from sector perform and slightly reduced the price target to $137 from $138.
Price: 94.93, Change: +4.06, Percent Change: +4.47
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.